JP2017535536A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535536A5
JP2017535536A5 JP2017522120A JP2017522120A JP2017535536A5 JP 2017535536 A5 JP2017535536 A5 JP 2017535536A5 JP 2017522120 A JP2017522120 A JP 2017522120A JP 2017522120 A JP2017522120 A JP 2017522120A JP 2017535536 A5 JP2017535536 A5 JP 2017535536A5
Authority
JP
Japan
Prior art keywords
carbazole
carboxamide
fluoro
tetrahydro
hydroxypropan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017522120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535536A (ja
JP6599983B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/057077 external-priority patent/WO2016065236A1/en
Publication of JP2017535536A publication Critical patent/JP2017535536A/ja
Publication of JP2017535536A5 publication Critical patent/JP2017535536A5/ja
Application granted granted Critical
Publication of JP6599983B2 publication Critical patent/JP6599983B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017522120A 2014-10-24 2015-10-23 カルバゾール誘導体 Active JP6599983B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068234P 2014-10-24 2014-10-24
US62/068,234 2014-10-24
PCT/US2015/057077 WO2016065236A1 (en) 2014-10-24 2015-10-23 Carbazole derivatives

Publications (3)

Publication Number Publication Date
JP2017535536A JP2017535536A (ja) 2017-11-30
JP2017535536A5 true JP2017535536A5 (enExample) 2018-11-08
JP6599983B2 JP6599983B2 (ja) 2019-10-30

Family

ID=54427879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017522120A Active JP6599983B2 (ja) 2014-10-24 2015-10-23 カルバゾール誘導体

Country Status (34)

Country Link
US (3) US10266491B2 (enExample)
EP (1) EP3209651B9 (enExample)
JP (1) JP6599983B2 (enExample)
KR (1) KR102514914B1 (enExample)
CN (1) CN107074804B (enExample)
AR (1) AR102427A1 (enExample)
AU (1) AU2015335703B2 (enExample)
BR (1) BR112017007545A2 (enExample)
CA (1) CA2965523A1 (enExample)
CL (1) CL2017001001A1 (enExample)
CO (1) CO2017004517A2 (enExample)
CY (1) CY1122549T1 (enExample)
DK (1) DK3209651T3 (enExample)
EA (1) EA032361B1 (enExample)
ES (1) ES2761903T3 (enExample)
HR (1) HRP20192197T2 (enExample)
HU (1) HUE048321T2 (enExample)
IL (1) IL251798B (enExample)
LT (1) LT3209651T (enExample)
MA (1) MA40302B1 (enExample)
ME (1) ME03754B (enExample)
MX (1) MX374724B (enExample)
MY (1) MY190568A (enExample)
PE (1) PE20171239A1 (enExample)
PH (1) PH12017500724B1 (enExample)
PL (1) PL3209651T3 (enExample)
PT (1) PT3209651T (enExample)
RS (1) RS59707B1 (enExample)
SG (2) SG11201703187PA (enExample)
SI (1) SI3209651T1 (enExample)
SM (1) SMT202000035T1 (enExample)
TN (1) TN2017000158A1 (enExample)
TW (1) TWI676618B (enExample)
WO (1) WO2016065236A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108506B (zh) 2014-10-24 2022-06-21 武田药品工业株式会社 杂环化合物
EA031614B1 (ru) * 2014-10-24 2019-01-31 Бристол-Майерс Сквибб Компани Трициклические атропоизомерные соединения
US10399988B2 (en) * 2016-07-07 2019-09-03 Daewoong Pharmaceutical Co., Ltd. 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
WO2019075386A1 (en) 2017-10-13 2019-04-18 The Regents Of The University Of California MODULATORS OF MTORC1
CN109053542A (zh) * 2018-07-25 2018-12-21 南通大学 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法
ES2965164T3 (es) * 2019-10-04 2024-04-11 Bristol Myers Squibb Co Compuestos de carbazol sustituidos
CN110862396B (zh) * 2019-11-29 2021-06-04 浙江工业大学 一种吡咯并[3,4-c]咔唑-1,3(2H,6H)-二酮类化合物的合成方法
KR20230009387A (ko) * 2020-04-10 2023-01-17 쥐비005 인코포레이티드 키나제 억제제
JP2023528421A (ja) * 2020-06-02 2023-07-04 ジービー005, インコーポレイテッド キナーゼ阻害剤
CN115232061B (zh) * 2021-09-18 2024-01-30 山西紫罗蓝新材料科技有限公司 一种3-硝基-9-乙基咔唑粗产物的提取工艺
MA71392A (fr) * 2022-07-06 2025-04-30 Vividion Therapeutics, Inc. Compositions pharmaceutiques comprenant des inhibiteurs de l'hélicase wrn
CR20250159A (es) * 2022-09-29 2025-07-04 Vividion Therapeutics Inc Derivados de n–acriloilmorfolina como moduladores de keap1 y sus usos
WO2026067706A1 (zh) * 2024-09-30 2026-04-02 杭州邦顺制药有限公司 Keap1调节剂

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
EP1812442A2 (en) 2004-11-10 2007-08-01 CGI Pharmaceuticals, Inc. Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
AP2334A (en) 2004-12-17 2011-12-06 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2390135T3 (es) 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
RU2009113585A (ru) 2006-09-11 2010-10-20 Матрикс Лэборетериз Лтд. (In) Производные дибензофурана в качестве ингибиторов pde-4 и pde-10
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ,インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2707491A1 (en) 2007-12-13 2009-06-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
LT2247558T (lt) 2008-02-14 2022-04-11 Eli Lilly And Company Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
WO2009153720A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
ES2443948T3 (es) * 2008-12-19 2014-02-21 Bristol-Myers Squibb Company Compuestos de carbazol carboxamida útiles como inhibidores de quinasas
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
ES2733093T3 (es) 2009-02-13 2019-11-27 Nextivity Inc Control remoto para amplificador
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
CN103429595B (zh) 2010-11-15 2015-10-21 Viiv保健英国有限公司 Hiv复制的抑制剂
JP5859640B2 (ja) 2011-05-17 2016-02-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ブルトンチロシンキナーゼ阻害剤
CN104582705A (zh) 2012-01-10 2015-04-29 林伯士艾瑞斯公司 白介素-1受体相关激酶(irak)抑制剂和其用途
JP6139690B2 (ja) 2012-10-26 2017-05-31 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ブルートンチロシンキナーゼの阻害剤
MX2015016771A (es) 2013-06-25 2016-03-31 Squibb Bristol Myers Co Compuestos de carbazol carboxamida utiles como inhibidores de cinasa.
TWI648272B (zh) * 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 經取代之四氫咔唑及咔唑甲醯胺化合物
AR102426A1 (es) 2014-10-24 2017-03-01 Bristol Myers Squibb Co Compuestos de indolcarboxamida como inhibidores de btk
EA031614B1 (ru) * 2014-10-24 2019-01-31 Бристол-Майерс Сквибб Компани Трициклические атропоизомерные соединения

Similar Documents

Publication Publication Date Title
ME03754B (me) Derivaтi karbazola
AU2004223827B2 (en) Heterocyclic compounds and methods of use
ES2310758T3 (es) Derivados de isoquinolina sustituidos y metodos de uso.
KR101140474B1 (ko) 간세포 성장 인자 수용체의 억제제로서 유용한 융합된 헤테로시클릭 유도체 및 사용 방법
AU2003256481B2 (en) Substituted anthranilic amide derivatives and methods of use
CN114948963B (zh) 蛋白激酶抑制剂苯并内酰胺化合物
US6822097B1 (en) Compounds and methods of uses
KR101404290B1 (ko) 과다-증식성 장애 및 맥관형성과 관련된 질환을 치료하는데유용한 치환된 4-아미노-피롤로트리아진 유도체
ES2644873T3 (es) Derivados de 6-([1,2,4]triazolo[4,3-a]piridin-3-ilmetil)-1,6-naftiridin-5(6H)-ona como inhibidores de c-Met
ES2260277T3 (es) Compuestos de urea y sus procedimientos de utilizacion.
JP2020510092A5 (enExample)
EP1971604B1 (en) Pyrrolo-pyridine derivatives for the treatment of cancer diseases
JP2017510576A5 (enExample)
RU2018123779A (ru) Новые соединения
JP2013520407A5 (enExample)
JP2018507861A5 (enExample)
JP2016538316A5 (enExample)
WO2014078813A1 (en) Compounds and compositions for the treatment of parasitic diseases
AU2004269000A1 (en) Substituted 2,3-dihydro-1H-isoindol-1-one derivatives and methods of use
AU2003252011A1 (en) Substituted 2-alkylamine nicotinic amide derivatives and use there of
EA025520B1 (ru) N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
TWI915393B (zh) 作為雄激素受體調節劑的吲哚化合物
EP2961750A1 (en) Substituted 7-oxo-pyrido [2, 3-d]pyrimidines and their use for the treatment of egfr / erbb2 related disorders
JP2017513887A5 (enExample)
JP2022534501A (ja) 三環式化合物